Is ELV a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Carelon services and pharmacy expansion, with revenue (ttm) at ~$200 billion. The bear case rests on the dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Analysts covering it are spread from $393.00 to $492.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $393.00, +3.0% from the $381.43 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Carelon services and pharmacy expansion. Carelon, which includes CarelonRx and risk-based care services, grew operating revenue about 33 percent in 2025 to roughly $71.7 billion, aided by the CareBridge acquisition. The most optimistic analyst target on ELV is $492.00, +29.0% from the $381.43 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Elevance is heavily exposed to government programs, so Medicaid rate adequacy, Medicare Advantage rate notices, and ACA subsidy policy are all regulatory swing factors outside its control. Integration risk from acquisitions like CareBridge, litigation and audit exposure common to large payers, and the political sensitivity of health insurer profits add further uncertainty. Because insurance margins are thin, a few points of adverse medical loss ratio can move earnings sharply, which is a key reason the stock carries a low multiple. The most pessimistic published target is $393.00, +3.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Elevance Health (formerly Anthem) is a diversified health insurer and healthcare services company that covers roughly 45.6 million medical members as of mid 2025.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Carelon services and pharmacy expansion) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

ELV is the NYSE ticker for Elevance Health, a large US health insurer and healthcare services company formerly known as Anthem. It operates Blue Cross Blue Shield plans across 14 states and covers roughly 45.6 million medical members.

Anthem rebranded to Elevance Health in 2022 to reflect its broader ambition beyond traditional health insurance, including its Carelon health services and pharmacy businesses. The stock ticker changed from ANTM to ELV as part of that transition.

Elevance earns premiums from members across commercial, Medicare Advantage, Medicaid, and ACA marketplace plans in its Health Benefits segment. Its Carelon segment adds revenue from pharmacy benefits (CarelonRx) and risk-based care services, a faster-growing, services-oriented part of the business.